Luis Querol (Valencia, 1980) graduated in Medicine at University of Oviedo. He completed his residency in Neurology at the Hospital de la Santa Creu i Sant Pau in Barcelona.

In 2009 he was awarded a Rio- Hortega contract in the Neuroimmunology field in the group of Dr. Isabel Illa, where he developed his thesis on the role of autoantibodies in immune-mediated neuropathies.

During his last year of Rio Hortega contract, in 2012, he worked as a research associate in the Department of Neurology at Yale University (USA) in the group of Dr Kevin O’Connor, where he conducted projects related autoantibodies in multiple sclerosis and myasthenia gravis.

Led by Dr . Illa, he completed his Doctorate in Medicine at the Autonomous University of Barcelona in 2013, thanks to studies that identified antibodies with clinical utility in autoimmune neuropathies. In particular he described the anti- contactin antibodies in a characteristic subgroup of patients with CIDP, the first biomarker detected in CIDP with clinical utility.

After his US rotation he continued to work at the Neuromuscular Diseases Unit of the Hospital de la Santa Creu i Sant Pau, where he combines clinical care, with special interest in autoimmune disease of the peripheral nervous system, with the laboratory and translational research in the field of autoantibodies and immune-mediated neuropathies.

Luis Querol has received th Best Young Clinical Investigator CIBERNED 2013 award and the 2014 PK Thomas prize for best presentation in the field of neuropathies of the European Federation of Neurological Societies, both for his work with autoantibodies in CIDP.

Academic Training

• Graduate in Medicine (University of Oviedo), 2004
• Doctor in Medicine ( Autonomous University of Barcelona), 2013

Grants and Awards

• Rio- Hortega Research Contract (Instituto de Salud Carlos III), 2009-2012
• Juan Rodes Contract Research (Instituto de Salud Carlos III), 2013
• Award for Best Young Clinical Investigator CIBERNED, 2013
• PK Thomas Prize, EFNS, 2014

Areas of investigation

• Immunopathogenesis of CIDP, special interest on B cells and antibodies
• Role of B cells and autoantibodies in other neuroimmune diseases